Pilar Basabe

Prof. Pilar Basabe


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2010 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PBPilar Basabe
Pilar Basabe
MRM. de Román
M. de Román
IMI.S. Marcos
I.S. Marcos
David DiezDavid Diez
David Diez
ABA. Blanco
A. Blanco
JUJ.G. Urones
J.G. Urones

15 October 2005 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
PBPilar Basabe
Pilar Basabe
SDS. Delgado
S. Delgado
IMI. S. Marcos
I. S. Marcos
David DiezDavid Diez
David Diez
ADA. Diego
A. Diego
JUJ. G. Urones
J. G. Urones

21 September 2009 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
PBPilar Basabe
Pilar Basabe
OBOlga Bodero
Olga Bodero
IMIsidro S. Marcos
Isidro S. Marcos
David DiezDavid Diez
David Diez
ABAraceli Blanco
Araceli Blanco
JUJulio G. Urones
Julio G. Urones

23 August 2002 in Synthesis
Verified
Journal Article
Closed access
PDF file
PBPilar Basabe
Pilar Basabe
ADAlberto Diego
Alberto Diego
David DiezDavid Diez
David Diez
IMIsidro S. Marcos
Isidro S. Marcos
FMFaustino Mollinedo
Faustino Mollinedo
JUJulio G. Urones
Julio G. Urones
(-)-Hyrtiosal and its C-16 epimer have been prepared from sclareol in moderate yield. The absolute configuration of na­tural product (-)-hyrtiosal has being determined.

20 April 2015 in Marine Drugs
Verified
Journal Article
Open access
PDF file
AUAitor Urosa
Aitor Urosa
IMIsidro Marcos
Isidro Marcos
David DiezDavid Diez
David Diez
ALAnna Lithgow
Anna Lithgow
GPGabriela B. Plata
Gabriela B. Plata
PBPilar Basabe
Pilar Basabe
The first synthesis of Luffarin I, sesterterpenolide isolated from sponge Luffariella geometrica, has been accomplished from commercially available sclareol. The key strategy involved in this synthesis is the diastereoselective reduction of an intermediate ketone. Luffarin I against human solid tumor cell lines showed antiproliferative activities (GI50) in the range 12–17 μM.

30 December 2015 in Molecules
Verified
Journal Article
Open access
PDF file
AGAna Gil-Mesón
Ana Gil-Mesón
ARAlejandro Martín Roncero
Alejandro Martín Roncero
Ignacio E TobalIgnacio E Tobal
Ignacio E Tobal
PBPilar Basabe
Pilar Basabe
David DiezDavid Diez
David Diez
IMIsidro Marcos
Isidro Marcos
A series of sesterterpenoid bioconjugates with phospholipids and polyunsaturated fatty acids (PUFAs) have been synthesized for biological activity testing as antiproliferative agents in several cancer cell lines. Different substitution analogues of the original lipidic ether edelfosine (1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine) are obtained varying the sesterterpenoid in position 1 or 2 of the glycerol or a phosphocholine or PUFA unit in position 3. Simple bioconjugates of sesterterpenoids and eicosapentaenoic acid (EPA) have been obtained too. All synthetic derivatives were tested against the human tumour cell lines HeLa (cervix) and MCF-7 (breast). Some compounds showed good IC50 (0.3 and 0.2 μM) values against these cell lines.